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Abstract 
The use of fluorine-18 as a radionuclide for positron emission tomography (PET) has 
become increasingly popular over the last two decades and cancer and neurology 
clinical centres worldwide are increasingly establishing competence in this modality 
for diagnostic imaging. Progress has been particularly impressive for small molecule 
pharmaceutical candidates and low molecular weight affinity peptides, where 
clearance rates of the peptides in the body are compatible with the half-life of fluorine-
18 (t1/2 = 110 min). However high molecular weight proteins present challenges as 
they circulate and clear much more slowly. This review focuses on the methods used 
to radiolabel antibodies and their derivatives with fluorine-18 as tracers for PET. The 
very high specificity of these biomolecules for disease indicators at the molecular level 
makes labelling them attractive, however antibodies can circulate for days within the 
blood, with slow clearance times due to their high molecular weights, and this is 
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inconsistent with the relatively short half-life of fluorine-18. Thus, lower molecular 
weight fragments of antibodies present more realistic targets for labelling. This review 
describes the approaches and protocols which have been successfully used to 
radiolabel antibodies and particularly antibody fragments with fluorine-18, and 
highlights this challenging aspect of fluorine-18 labelling for PET imaging.  
 
Keywords: fluorine-18, positron emission tomography, antibody, antibody fragment, 
bioconjugation.  
 
1. Introduction  
Positron emission tomography (PET) is a widespread imaging modality for clinical 
applications such as: disease diagnosis, tumour detection and brain imaging [1].  The 
fluorine-18 isotope is particularly suitable for use as a positron emitter owing to its half-life 
(t1/2 = 110 min) which is long enough to achieve relatively elaborate synthetic sequences 
from cyclotron generated fluoride-18. When compared to other commonly used 
radionuclides; oxygen-15 (t1/2 = 2 min), nitrogen-13 (t1/2 = 10 min) and carbon-11 (t1/2 = 20 
min), the longevity of fluorine-18 represents a clear advantage. Furthermore, the positron 
emission energy of fluorine-18 is weaker than all other first row positron emitters which 
optimises resolution in imaging [2,3]. On the other hand, the half-life of fluorine-18 is short 
enough to achieve a high signal to noise ratio on a timescale which complements the 
pharmacokinetic profile of pharmaceutical type molecules of interest, in contrast to more 
persistent heavier radionuclides [4].  
Consequently, there is a mature research activity focussed on radiolabelling with the 
fluorine-18 isotope. To date the focus has been on low molecular weight drug like molecules 
and extending to bioactive peptides with molecular weights in the 1-4 kDa range. The area 
has been the subject of a number of recent comprehensive reviews [5–9]. With the advent of 
antibody engineering technologies, there has been a steady interest in exploring technology 
for the radiolabelling of antibodies for clinical imaging, due to their exquisite affinity to 
molecular markers of disease on cell surfaces. Early reports tended to focus on the labelling 
of whole antibodies (160 kDa) but clinical applications have been hindered by slow 
circulation kinetics resulting from their high molecular weights [10]. Typically, antibodies 
circulate in the blood for several days rendering them incompatible with fluorine-18 due to a 
disparate shorter half-life. As a result, efforts to radiolabel smaller antibody fragments (25-
110 kDa), which circulate much more rapidly, have been pursued and with more success. 
These fragments are composed of various derivatives of their parent antibodies (Fig. 1.) but 
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universally incorporate an antigen-binding site to retain binding affinity. To reduce molecular 
weight further the radiolabelling of even smaller non-antibody, antigen-targeting molecules 
known as affibodies (6.5-14 kDa) has been explored and these possess additional 
advantages such as chemical stability [11]. 
The limited half-life of fluorine-18 demands that isotopic incorporation into the biomolecule is 
completed as fast as possible to prevent excess radioactive decay. The fluorine-18 isotope 
is generated in a cyclotron wherein the bombardment of oxygen-18 enriched water [18OH2] 
with high energy protons generates an aqueous solution of fluoride-18 in pico- to nano- 
molar concentrations [3]. Difficulty arises when attempting to utilise this solution for labelling 
because of the poor nucleophilicity of aqueous fluoride [12]. Methods generally rely on a 
drying step wherein water is removed and fluoride-18 is fixed as its potassium salt in an 
aprotic organic solvent with a phase transfer catalyst (usually kryptofix) to bind K+. The 
resulting organic solution containing soluble fluoride-18 ion is then used to radiolabel a 
prosthetic group which can be selectively conjugated to a desired moiety on the biomolecule 
[13]. Recently efforts have been made to circumvent the need for drying entirely. These 
strategies include; exploitation of the labile B(boron)-F bond to facilitate isotopic exchange in 
aqueous media [14], the use of chelating ligands to trap Al(aluminium)-fluorine-18 [15], 
aqueous inverse electron demand Diels-Alder (IEDDA) reactions [16] and enzymatic 
methods [17]. Also of note are pre-targeting strategies which typically involve the injection of 
an antibody-streptavidin construct several days prior to administration of a low molecular 
weight fluorine-18 tagged biotin [18].  
 
Antibody and antibody fragments {Note to Editor: This section should appear as an 
information inset} 
Antibodies are large proteins (immunoglobulins - Igs) which have different functions in the 
immune system. Immunoglobin G (IgG) is the most abundant (Fig. 1). Structurally they have 
two heavy (H) and two Light (L) polypeptide chains, held together through disulphide 
bridges.  The H and L chains can be divided into variable (V) and constant (C) domains. The 
variation in the VH and VL chains determines the unique antigen-recognition site. IgG has a 
high molecular weight of 160 kDa, resulting in its persistence in the circulatory system for 
several days after injection. However, molecular weight fragments of the antibody present 
better candidates for radiolabelling as their uptake and clearance times are more rapid. In 
this review radiolabelling of several categories of engineered antibody fragments are 
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highlighted. This inset provides an indication of the topology of the different fragment 
categories.  
The Fc region of antibodies is not associated with antigen binding but fulfils a number of 
biological roles; it binds to receptors on target cells and confers effector functions which 
result in the destruction of the targeted cell [19,20]. The Fab region is the antigen-binding 
domain and is therefore integral to biotechnological applications. The region consists of two 
constant domains (the light domain CL and the heavy domain CH1) and two variable domains 
(the light domain VL and the heavy domain VH) the latter of which is responsible for the 
unique specificity of the antigen binding site. The antibody fragments discussed here will 
include; the F(ab’)2 homodimer fragment (~110 kDa), the Fab’ fragment (~55 kDa), the Fab 
fragment (~50 kDa) and the Fv/scFv fragment (~25 kDa). Diabodies (~55 kDa) are non-
covalent dimers of the Fv fragment ((Fv)2) or the scFv fragment ((scFv)2), in the case of cys-
diabodies a free thiol moiety is present which leads to disulphide-stabilisation. The (Fab’)2 
homodimer consists of both Fab regions linked by disulphides and therefore retains the 
entire binding region of the antibody. The Fab’ fragment is derived from the homodimer by 
enzymatic reduction and retains a free thiol group. In contrast, the Fab fragment does not 
retain the thiol moiety and consists only of the four domains (CL, CH1, VL and VH) linked by 
disulphide interactions. In contrast Fv and scFv consist only of the two variable domains (VL 
and VH) and in scFv fragments these variable domains are linked by a hydrophilic peptide 
chain consisting of about 15 amino acid residues. Similarly a dsFv fragment is based on Fv 
but with an interchain disulphide bond [20,21]. A promising class of engineered proteins are 
affibodies which combine the recognition properties of antibodies with several desirable traits 
including small size (6.5-14 kDa) and increased stability to heat and harsh chemical 
conditions. Affibodies consist of 58 amino acids arranged into three helices. Of these, 13 
residues may be subject to mutagenesis to determine the specificity of binding. These 
residues have been varied combinatorially to provide extensive libraries of affibodies each 
with a unique binding site on a target antigen [22][23].  
Another class of Immunoglobulin G is the camelid-derived heavy-chain variant which 
possesses a non-binding region as found in the Fc region of conventional IgG but a distinct 
binding region consisting only of a single variable domain VHH. The VHH fragment is also 
known as a nanobody, reflecting its relative low molecular weight (12-15 kDa) which aids its 
biotechnological application. Furthermore, nanobodies possess properties such as low 
immunogenicity and high stability which make them particularly suitable probes [24].   
{Note to Editor:  End inset here} 
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2. Strategies for fluorine-18 labelling of antibodies and their fragments  
 
Early methods for the radiolabelling of antibodies and derivatives utilised radiolabelled small 
molecules  for conjugation (Fig. 2). The first application of fluorine-18 for antibody labelling 
was reported in 1987 when the alkylating agents 7 and 8 were used to radiolabel the 
antibody IgA (162 kDa) [25]. The synthesis of 7 (20-33% yield, 45-50 min) was achieved 
from SNAr of 3,5-dinitrobenzonitrile no carrier added (n.c.a.) fluoride-18, followed by the 
addition of sodium methoxide. The synthesis of 8 (28-40% yield, 75 min) also began with an 
SNAr utilising n.c.a. fluoride-18 with 4-nitrobenzonitrile and was elaborated to the final 
product by addition of MeLi and CuBr2. Antibody conjugation was conducted under ambient 
aqueous conditions (borate buffer, pH 8.0, 47 °C, 1 h). The radiochemical yields (RCY) for 
the labelling of IgA were 16% for 7 and 46% for 8.  
Later, 8 was utilised to label the F(ab’)2 fragment of the murine BB5-G1 antibody (specific for 
a human parathyroid antigen) in 10% yield (from 8) [26]. The labelled fragment displayed 
specificity of 10:1 parathyroid-to-muscle after 4h in nude mice models.   
Later the mouse Mel-14 antibody (Fab’)2 fragment was radiolabelled with fluorine-18 
[13,27,28]. Radiolabelling was achieved using 1, which was synthesised by SNAr of 10 to 
give 6 (Scheme 1). Subsequently, oxidation and N-hydroxysuccinamide (NHS) coupling 
were used to obtain 1 (100 min, RCY 25%). Conjugation was achieved under ambient 
aqueous conditions (pH 8.5 borate buffer, 15-20 min) in a 40-60% yield which was an 
improvement relative to the previously described methods involving 7 and 8. In vitro binding 
and mouse tissue distribution studies showed similar results to those observed for the 
antibody fragment tagged with the 125I analogue of 1. Later refinements to the method 
reduced the synthesis and purification time of 1 to about 45 mins [29]. These included an 
increased temperature for all steps and the use of dicyclohexyl carbodiimide (DCC) as the 
coupling promoter.  
Additional early work utilised the prosthetic group 3 [30–34]. The synthesis of 3 usually 
begins with an SNAr reaction of 11 with tetrabutylammonium [18F]fluoride to give 12. Amide 
coupling with 12 gives 3 (Scheme 2). Conjugation to the MeI-14 F(ab’)2 and the TP-3 Fab 
fragments were achieved under analogous conditions as developed for 1. A comparative 
study showed that the total synthesis time (85 min) for 3 was shorter than that (95 min) for 1, 
but that the overall radiochemical yields were similar  (RCY 10-12%) [30]. 
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Attempts to improve upon 1 as a prosthetic group continued with the exploration of 9 for 
radiolabelling of IgG and the IL-2α dsFv fragment [35,36]. The synthesis of 9 is achieved by 
an SN2 reaction of 13 with fluoride-18 (Scheme 3).  This significantly reduced the preparation 
time (30-35 min) relative to 1, although RCYs (10-20%) were modest due to the formation of 
a side product resulting from ester cleavage. Labelling of IgG (borate buffer, pH 8.5, 10-15 
min) was achieved in a 50-70% yield. The overall RCY was 10% and accomplished in 65 
min including purification. The labelling of the IL-2α Fv fragment (borate buffer, pH 8.5, 10 
min) with 9 was achieved in 33-45% yield [36–38].  
Wester et al., compared 1 and 5 as tags for radiolabelling antibody IgG [12]. Their improved 
synthesis of 1 was achieved in a 35% RCY in 55 min (Scheme 5). Subsequent labelling of 
IgG was achieved (borate buffer, pH 8.5, r.t, 15 min) in 48-60% RCY. Azeotropically dried 
[18F]fluoride was used to convert 14 to 5 in an efficient 70% RCY in 4 min (Scheme 4). 
However, the labelling of IgG with 5 (15W UV lamp, 365 nm, 5 min) proceeded in a low RCY 
of 11%. Notably 5 is conjugated to the antibody by a photochemical reaction proceeding 
through a nitrene intermediate. The reduced RCY in this case was attributed to the short 
lifetime of the nitrene and presents a limitation for using 5, despite its high-yielding one-step 
preparation from [18F]fluoride. 
A comparative study by Reske et al. contrasted the use of fluorine-18 and technetium-99m 
as radiolabels for the leukemia relevant anti-CD66 antibody [39]. The chosen prosthetic 
group 1 was prepared by automated synthesis (Scheme 5) giving a decay-corrected 
radiochemical yield (dcRCY) of 32% in 75 min. Conjugation to anti-CD66 (borate buffer, pH 
8.5, r.t., 10 min) was achieved in a 9-14% RCY. Unusually for whole antibodies, anti-CD66 is 
notable for its fast blood clearance and its fast uptake by bone marrow tissue [40]. 
Consequently, anti-CD66 is suitable for use on the fluorine-18 isotope timescale and the 
report indicates that the labelled antibody provided excellent PET image quality and a clear 
selectivity for bone marrow tissue. 
Cai et al. reported the use of 1 to radiolabel the anti-carcinoembryonic (CEA) T84.66 
diabody ((scFv)2) [41]. The authors note that the use of the diabody is preferred to the scFv 
fragment because the former is capable of bivalent binding (relative to monovalent binding 
for scFv) which results in increased tumour uptake and retention while retaining a low 
enough molecular weight to be cleared from the blood on the fluorine-18 timescale. The 
synthesis of 1 (27-38%, 130-146 min) was acheived in an automated module according to 
standard protocols (Scheme 1). However, the labelling of T84.66 (borate buffer, pH 8.5, 40 
°C, 30-40 min) was inefficient due to a limited number of accessible lysine residues on the 
diabody surface. As a result, the overall dcRCY was just 1.2-1.6%. The labelled diabody 
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showed high tumour uptake for CEA positive tumours in mouse models and high-contrast 
PET images were viewable within 1 h of injection. 
The anti-CEA T84.66 diabody has been engineered to incorporate a terminal cysteine 
residue which results in a disulfide bond between the subunits of the dimer giving a cys-
diabody. The cys-diabody has been radiolabelled using 1 [42,43]. The synthesis of 1 (35% 
RCY, 40 min) involved a one-pot microwave-assisted process adapted from Scheme 1. The 
cys-diabody was radiolabelled (borate buffer, pH 8.5, r.t., 30-45 min) with 1 resulting in an 
overall decay-corrected RCY of 1.8-2.5% in 100min. 
Additionally, 1 has been used to label an anti-LIBS scFv [44]. The fragment in question binds 
the platelet integrin receptor IIb/IIIa and is an attractive target for the detection of activated 
platelets in carotid artery thrombosis. The synthesis of 1 was completed according to a 
previously reported protocol adapted from Scheme 1 [45,46]. Crucially, the use of an 
automated synthetic module facilitated improvement in dcRCY of 1, typically 80% in 58 min. 
Labelling of ScFvanti-LIBS (phosphate buffered saline, Ca2+/Mg2+, 30 min) proceeded in an 
overall RCY of 1.3-2.3%. Mice PET studies demonstrated a greater uptake for the labelled 
fragment at injured vessels compared to intact ones, indicating the selectivity required for 
diagnostic imaging of thrombosis. 
The use of 1 for the labelling of an anti-MMR camelid nanobody was reported in 2015 [47]. 
The synthesis of 1 was automated and modular, facilitating a one pot synthesis, and with a 
RCY of 50-60% in 50 min (Scheme 5). Conjugation to the nanobody (borate buffer, pH 7.4-
9.0) gave a decay corrected RCY of 20-30%. The tracer displayed specificity for 
macrophage mannose receptors (MMR) and produced the desired biodistribution in mice 
models.  
The anti-HER2 nanobody has also been radiolabelled using 1 [48]. The automated, modular 
synthesis of 1 was further optimised giving a dcRCY of 60-70%. The anti-HER2 nanobody 
was successfully labelled (borate buffer, pH 8.4-8.5, r.t., 20 min) in a 20-30% dcRCY 
resulting in an overall dcRCY of 5-15% in 180 min. The tracer’s specificity to the HER2-
antigen was successfully shown in mice, generating high contrast PET images. 
Recently 1 was used to radiolabel the scFv fragment of the anti-CA125 antibody B43.13 [49]. 
The target antigen is associated with epithelial ovarian cancer. The automated synthesis of 1 
was adapted from Scheme 5 and gave a dc-RCY of 48-86% in 54-62 min. Radiolabelling of 
the scFv fragment (borate buffer, pH 8.3, 45 min, 30 °C) was achieved, resulting in an 
overall dc-RCY of 1.9-5.6%. In mice models a modest uptake was achieved and the authors 
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note that while scFv fragments are attractive for fluorine-18 PET because of their rapid blood 
clearance, their small size results in their rapid renal clearance. For this reason and that of 
increased binding efficiency the authors suggest cys-diabodies as better candidates for 
tumour uptake in PET. 
The anti-VCAM-1 nanobody, cAbVCAM1-5 has been labelled by 1 [50]. The radiosynthesis 
of 1 was achieved utilising a method similar to standard protocols (Scheme 1, Scheme 5) in 
50-60% RCY [47]. Conjugation (borate buffer, pH 8.5, 20 min, r.t.) to the nanobody was 
achieved facilitating PET studies in mice which imaged atherosclerotic lesions. 
Optimisation of the conjugation between 1 and biomolecules has extended to the use of a 
digital microfluidic droplet generation (DMDG) chip [51]. The radiosynthesis of 1 was 
performed in a one-pot microwave-assisted process modified from previous procedures 
(Scheme 1, Scheme 5) in 30-40% RCY within 60 min. The DMDG chip facilitates precise 
control of conjugation mixture composition (1, biomolecule, buffer (variable pH)) at the 
nanolitre scale. The chip can therefore be used to screen a variety of conditions for a given 
system before scaling up the optimised protocol, specifically pH and biomolecule 
concentration. To demonstrate this utility the DMDG chip was used to optimise labelling 
conditions for the anti-PSCA A2 diabody and; a pH of 8.7, a volumetric ratio of 1:2 
(1:diabody) and a diabody concentration of 1 mg/mL-1 were found to give optimum labelling 
yields. On scale-up a RCY of ~23% was achieved in 10-20 min. MicroPET imaging of 
tumours in xenografted murine models were viewable within 30-240 min. The DMDG chip 
was further utilised for the conjugation of 1 and an anti-HER2 diabody. Optimised conditions 
(pH 8.6, 0.33 mgmL-1) were used to obtain the conjugate in 18% RCY which facilitated 
microPET imaging of xenografted murine models. 
Two antibody fragments that target the αvβ6 integrin (a diabody and a cys-diabody) have 
been radiolabelled using 1 [52]. The radiosynthesis of 1 was achieved using a standard 
protocol (Scheme 5) and gave 34-38.% RCY in 62-64 min. Conjugation to the diabody and 
cys-diabody were performed according to the DMDG optimised conditions for 1 (borate 
buffer, pH 8.7, 37 °C, 10 min) in 7-10% and 19-26% RCY respectively. The authors note that 
specific DMDG optimisation for the diabodies under investigation could improve the RCY. 
Recently Vaidyanathan et al. sought to implement a ‘residualising’ label to extend the 
radioactive time profile of the target [53]. Some antigens are internalising, meaning that they 
become incorporated within the target cell after binding. After internalisation, proteolysis of 
the conjugate takes place in the lysozyme. Non-residualising products from the catabolism 
such as [18F]fluoride, are likely to be removed quickly from the cell resulting in a loss of 
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radioactivity.  Residualising labels are retained at the target and their catabolites can be 
retained within the lysozyme and are therefore less likely to be removed from the cell. 
Nucleophilic substitution of 19 gave 20 which was immediately exposed to 18 under CuAAC 
conditions. After a ‘click’ reaction, deprotection of the guanidinium residue yielded 21 
(Scheme 6, dcRCY 5.8-11.3%, 100 min). Labelling of the anti-HER2 sdAb 5F7 (borate 
buffer, pH 8.5, 20 °C, 20 min) proceeded in an overall dcRCY of 2-3%. For comparison, the 
1-nanobody conjugate was prepared. Radiolabelling of the nanobody with 1 was achieved in 
26-49% RCY. Crucially the 21-nanobody conjugate displayed significantly higher 
accumulation and retention in target cells and xenografted mice than was observed for the 1 
conjugate, consistent with the residualizing nature of 21 [54].  The use of 21 was further 
extended to label another anti-HER2 sdAb, 2Rs15d which binds to a different site of HER2 
(making it compatible with trastuzumab/pertuzumab therapy) [55]. A similar labelling protocol 
gave RCYs in the range 30-59%. The resulting conjugate had a lower tumour retention in 
vivo and in vitro than the 5F7 conjugate. 
The prosthetic group 4 has been used for the radiolabelling of the affibody ZEGFR:1907 [56]. 
Beginning with 1, amide coupling with 22 was used to synthesis 4 (Scheme 7). With 4 the 
affibody was labelled site-specifically through the N terminus cysteine residue in buffered 
conditions (pH 7, 40 min). The authors note in a later paper that the total synthesis time and 
yield (3h, RCY 10%) for affibody preparation  placed limitations on routine use of 4-ZEGFR:1907 
as an imaging agent [57].   
Similarly, two HER2-specific affibodies ZHER2:342 and ZHER2:2395 were radiolabelled using 4 
[58,59]. Unlike before, the synthesis of 4 proceeded via the formation of 16 which underwent 
diethyl cyanophosphonate-mediated amide coupling (RCY 17-27%). Conjugation (PBS, pH 
7.4, r.t., 30 min) was achieved in RCY’s up to 60% and in overall RCYs of between 9-13% in 
approximately 2 hours. The radiolabelled ZHER2:342 was used to image xenografted mice and 
a retention of binding specificity was observed. The labelled affibody ZHER2:342 has more 
recently been applied to monitor activity of a candidate anti-cancer drug and known HER2 
down regulator, 17-DMAG [60]. The ability of the conjugate to image HER2 expressing 
tumours quantitatively was shown to facilitate its assessment of drug candidates. Similarly, 
the conjugate was utilised to quantify tumour responses to chemotherapeutic treatment with 
trastuzumab [61]. Animal studies indicated a lower uptake of the conjugate after 
administration of trastuzumab consistent with a downregulation of HER2. 
The prosthetic group 6 has been utilised to radiolabel two Anti-HER2 affibody molecules 
[62]; the monomeric ZHER2:477 and the dimeric (ZHER2:477)2. The synthesis of 6 was performed 
using the procedure in Scheme 1 and gave the product in a dcRCY of between 50-70% in 40 
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min. Labelling of the affibody (ammonium acetate, pH 4, 70 °C, 15 min) was achieved 
resulting in an overall dcRCY of 13-18% in a total of 100 min. 
The use of 6 has also been extended to two synthetic variant affibodies of ZHER2:342 [63]. The 
synthesis of 6 was performed using the method in Scheme 1 and gave the product in 50-
70% RCY. The affibody fragments were successfully labelled (citrate, phosphate, MeCN, pH 
2.6, 70 °C, 15 min) in an overall dcRCY of 3-5%. 
Similarly, 6 has been used to radiolabel Anti-HER2 dimeric affibody via oxime ligation [11]. 
The radiosynthesis of 6 was as before (Scheme 1) and proceeded in 50-70% dcRCY within 
40 min. The affibody was pre-functionalised to provide an aminooxy handle and was 
conjugated to 6 (ammonium acetate, pH 4, 70 °C, 15 min) in 26-30% dcRCY.  
Another anti-HER2 affibody ZHER2:2891 was recently labelled with 6 [64] and conjugation 
(aniline hydrochloride, water, 70 °C, 20 min) followed in an overall RCY of 30%. Uptake of 
the conjugate was greater for HER2-positive than for HER2-negative cell lines which 
indicates suitability in distinguishing the more aggressive positive tumours from less 
aggressive negative ones.   
A modular approach exploiting the CuAAC click reaction has been developed for the 
radiolabelling of the trastuzumab fab fragment [65]. The triazole 26 was prepared by click 
reaction with 24 (Scheme 8) in 50-59% yield from the unlabelled azide 23. Notably, 26 has 
the benefit of improved water-solubility relative to other prosthetic groups due to the 
hydrophilicity of the PEG linker which can be extended if desired. The trastuzumab Fab 
fragment was radiolabelled using 26 (phosphate buffer, pH 8, r.t., 10 min) with a conjugation 
efficiency of 23-37%. Overall the dcRCY was 10-16% which was obtained between 78-86 
min. The labelled fragment was shown to be an effective PET tracer for the imaging of HER2 
receptors in murine models.  
Rosa-Neto et al. have developed a method for fluorine-18 labelling of bovine IgG with a 
silicon-containing prosthetic group, 28 [66]. The pre-assembled prosthetic group is 
radiolabelled by a one-step isotopic exchange with 27 to give 28 (Scheme 9) in 95% RCY. 
Labelling occurs by the amidation of the isothiocyanate (carbonate buffer, pH 9, r.t., 10-20 
min) and gave a RCY of 40%. The overall RCY was approximately 38% obtained in a total of 
40-50 min.  
Another Si-based prosthetic group 30, has been utilised to label a β-cell-specific scFv 
fragment [67]. The pre-assembled prosthetic group is radiolabelled in a one-step isotopic 
exchange with 29 to obtain pure 30 (Scheme 10) in 20-25 min and a 56% RCY. The fluorine-
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18 was obtained without azeotropic drying according to the rapid Munich method which 
utilises a strong anion exchange (SAX) cartridge to trap aqueous fluoride-18 [67,68]. A 
drying step is usually required due to the poor nucleophilicity of aqueous fluoride [69]. The 
labelling of the scFv fragment with 30 (borate buffer, pH 9, r.t., 30 min) gave a RCY of 17-
19% and can be compared to that with 1 (borate buffer, pH 9, r.t., 20 min) in a RCY of 11-
17%.  
A recent report details the preparation and application of a new heterocyclic prosthetic group 
32 based on Barbas linkers [70]. Synthesis involved readily available precursors and the 
radiolabel was introduced in the final step by SN2 reaction with 31 (Scheme 11) which gave 
32 in 21-33% dcRCY in 10 min. With 32 in hand conjugation (PBS, 50 °C, 15 min) to the 
modified affibody ZHER2:2395-Cys was achieved in 40% RCY. Notably negligible conjugate was 
recovered at 37 °C. The total synthesis, conjugation and purification time was about 160 min 
and the authors noted an unusually high specific activity of the conjugate. Additional 
advantages of 32 were cited as a single-step synthesis with a single product and the stability 
of its conjugates in vivo.  
An attractive approach to fluorine-18 radiolabelling involves the direct use of aqueous 
fluoride-18 from the cyclotron. However, this method requires water soluble substrates that 
are sufficiently fluorophilic to sequester aqueous fluoride. Smith et al. [18], used aqueous 
fluoride-18 to label an antibody in a pre-targeting approach, by exploiting the biotin-avidin 
interaction. Beginning with 33, radiolabelling was achieved by treatment with an acidic, 
aqueous solution of fluoride-18 to give 34 (Scheme 12) in 2 h and 65% yield. Following the 
incubation of three separate HER2 expressing cell lines with NeutravidinTM conjugated 
trastuzumab 34 was added and exhibited binding to those cells. Notably the cells expressing 
HER2 at higher levels displayed greater binding to 34 indicating the sensitivity of the 
approach. These in vitro results indicate the potential of the pre-targeting method for clinical 
applications. 
A similar pre-targeting approach has utilised the lability of the B-F bond to radiolabel 
dendron-containing 35 giving 36 which bound to HER2 cells pre-targeted with avidin-
trastuzumab [71]. The radiolabel was introduced in the final step (37 °C, 1 h) utilising either a 
trifluoroboroaryl handle or the pinacolboryl moiety (Scheme 13). In either case labelling 
efficiency was about 60%. The efficacy of the pre-targeting approach was shown in vitro but 
in vivo results are pending further investigation. 
An alternative and more widely explored method to label antibody fragments and other 
biomolecules with aqueous fluoride-18 was developed by Lütje, McBride et al. [15,72], 
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wherein the preparation of the aluminium-fluorine-18 bound ligand 38 is described. 
Beginning with the unbound ligand 37, 38 is obtained within 60 mins (Scheme 14) with a 
labelling efficiency of 92-96% and a high specific activity following solid phase extraction of 
unbound fluoride-18. Conjugation of 38 (citrate buffer, pH 6.0, r.t., 20 min) to various 
fragments of the hMN-14 Anti-CEA antibody (Fab’, (scFv)2, Fab-Ad2) proved efficient (RCY 
70-77%), and gave overall purified yields in the range of 49-66%.  
Utilising similar methods, the radiolabelling of affibody, ZEGFR:1907 has been achieved [57]. 
This affibody has a known affinity for the epidermal growth factor receptor (EGFR) a 
validated target for cancer imaging. The prosthetic group 39 was prepared and conjugated to 
the affibody via a cysteine residue (Scheme 15). This allowed last-step radiolabelling of the 
40 with Al[18F] in 15 min which gave 41 in an overall dcRCY of 15% within 40 min. This 
method was compared to affibody radiolabelling via the more conventional prosthetic group, 
43 [73]. The synthesis of 43 was achieved by a SN2 reaction on 42 (Scheme 16). Affibody 
labelling (PBS, pH 8, 60 °C, 20 min) resulted in an overall dcRCY of 41% in 2 hours. A 
comparison of the methods clearly displays a significant time benefit on utilising aqueous 
[18F]fluoride directly without an additional azeotropic drying step. On the other hand, the 
dcRCY was higher for the 43-affibody conjugate (41%) than for the 41-affibody conjugate 
(15%). Both probes displayed effective imaging of EGFR-expressing tumours in murine PET 
models.  
The human epidermal growth factor HER2, has been targeted using the fluorine-18 labelled 
cys-affibody cys-ZHER2:2395 in a mouse model for ovarian cancer [74]. The reduced affibody 
cys-ZHER2:2395 was incubated with 38 to enable last-step radiolabelling. Radiolabelling was 
achieved using an analogous model to that described in Scheme 15, achieving an RCYs of 
around 25% in 30 min. The conjugate was shown to retain affinity for HER2 expressing cells 
in vitro and in vivo (producing PET images). 
A recent comparative study contrasted four established labelling agents for the fluorine-18 
labelling of the HER2-binding affibody ZHER2:2891 [75]. The affibody was first modified through 
an engineered cysteine at the C terminus to allow coupling through maleimide linkers.  The 
prosthetic group 6 was synthesised following the protocol in Scheme 1 (RCY 38-48%) and 
was then conjugated to cys-ZHER2:2891 (aniline hydrochloride, water, 70 °C, 20 min). The total 
synthesis and conjugation time took 60-65 min and the overall RCY was 10-16%. The 
complexing agent 39 was also utilised in this study following the standard protocol in 
Scheme 15. The overall RCY of the radiolabelled affibody conjugate was 7-15% with a 
synthesis and conjugation time of 26-28 min. A further aluminium fluoride strategy was also 
explored using 44. In this case synthesis and conjugation to the affibody to generate the 
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radiolabelled conjugate took 33 min with a RCY of 8%. A final labelling agent 45 exploited 
the strong silicon-fluoride ion affinity. Sufficient lability of the Si-F bond allowed aqueous 
fluoride-18 to be used to generate 45 by displacement of an unlabelled fluoride, as 
previously described (Scheme 9). Conjugation was then achieved (pH 4.0, 15 min, 95 °C) in 
a RCY of 36-40% in 30-35 mins.  
The aluminium-fluoride method has recently been adapted to incorporate a biorthogonal 
inverse electron demand Diels-Alder (IEDDA) click route to antibody radiolabelling [76]. 
Radiolabelling of 46 with AlCl3 and aqueous [18F]fluoride gave 47 in approximately 35 min 
and with dcRCY 54-65% (Scheme 17). To obtain a suitable handle for the required IEDDA 
conjugation, the selected antibody antiCA19.9 5B1 was incubated with an activated 
succinimidyl ester of trans-cyclooctene (TCO-NHS). The resulting TCO modified 5B1 was 
conjugated to the prosthetic group under ambient conditions (PBS, pH 7.4, r.t., 15 min) 
giving >94% RCY (Overall RCY 51-61%). The resulting radiolabelled 5B1 was shown to 
effectively visualise pancreatic cancer xenografts present in mice.  
Recently two aluminium fluoride binding ligands have been used for radiolabelling the 
ZHER3:8698 affibody for successful imaging of HER3 positive tumours in mice [16]. Firstly, 39 
was conjugated to ZHER3:8698 via an engineered cysteine residue with last-step radiolabelling 
as before (Scheme 15). The RCY was 10-27% and the radiochemistry and purification took 
approximately 50 min. Additionally 48 (Figure 5) was radiolabelled using the protocol in 
Scheme 17 with a RCY of 70-95% in 15 min. The radiolabelled ligand was then used to form 
the affibody conjugate with the TCO-modified ZHER3:8698 via an IEDDA as before. This gave 
an overall protein recovery of 34-55% in 70 min. By comparison the last-step 39 labelling 
strategy benefits from a reduced radiolabelling time of 50 min relative to the two-step 48 
strategy, but this can be at the expense of yield. In the last-step labelling strategy the 
biomolecule is exposed to high temperatures (90-100 °C) which may result in degradation of 
sensitive biomolecules, thus the 48 strategy is more suitable for heat-sensitive compounds. 
Work by Hendricks et al. describes a novel hybrid fluorine-18 imaging agent providing 
access to a PET/fluorescence molecular tomography (FMT) hybrid 50 [77]. Synthesis of 50 
from 49 was achieved in a one-pot two-step process (Scheme 18) in 2 min with a total 73% 
RCY. Following synthesis, 50 was used to radiolabel trastuzumab – a HER2 monoclonal 
antibody. Radiolabelling was achieved (PBS, r.t., 15 min) in 19.9% decay-corrected RCY. 
Rodriguez et al. have recently reported the use of a dioxaborolane strategy for the 
preparation of fluorine-18 labelled monoclonal antibodies for PET [14]. Like the aluminium 
fluoride methods the dioxaborolane approach avoids the less convenient [18F]fluoride drying 
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steps involved in the preparation of prosthetic groups. The unlabelled antibody conjugate 51 
also contains a biotin handle for solid support and a hydrophilic heptacyanine optical probe. 
In the labelling step 51 was immobilised on a solid-phase support and exposed to aqueous 
[18F]fluoride. The resulting fluorolysis cleaved the conjugate from the solid support, releasing 
the radiolabelled antibody conjugate 52 and the remaining biotinylated 53 (Scheme 19). The 
inclusion of the optical probe allows for a PET-near infrared fluorescence (NIRF) multimodal 
imaging strategy.  
The use of [18F]FDG 2 as an imaging agent for PET is well established due it is particular 
ability to localise in a range of cancer cell types in vivo and it is the most widely used tool in 
PET diagnosis [78]. Consequently, 2 is available in most clinical radiochemical environments 
specialising in PET and this makes it an ideal starting point for prosthetic group syntheses 
for the labelling of biomolecules. Rashidian et al. have reported the synthesis of the VHH 
conjugate 58 [79]. Firstly, the reaction of 2 with 54 trapped the open chain 55. Meanwhile, 
sortase substrate 56 was exposed to sortase and the nanobody preconjugate VHH-LPETG-
XX and the resulting biotransformation gave the TCO-nanobody conjugate 57. A rapid click 
reaction between 55 and 57 gave the radiolabelled antibody 58 (Scheme 20). The total 
synthesis time from 2 was 25 mins and RCY were in excess of 25%. The labelled antibody 
conjugate was used to successfully detect small heterotopic pancreatic tumour transplants in 
mice by PET imaging.  
Further work from Rashidian et al. has demonstrated that the substrate scope for the 
sortase-mediated process facilitates modular assembly (Scheme 21) [80]. Firstly, 1 was 
elaborated to monomeric VHH conjugate 61. This was achieved by first amide coupling 1 
with 59 to give 60. Meanwhile, the sortase product 57 was prepared as previously (Scheme 
20). The click reaction between 57 and 60 gave the conjugate 61.  
Alternatively, 60 underwent a ‘click’ reaction with the bifunctional (azide and TCO-containing) 
sortase product 62 followed by exposure to DBCO-modified VHH, to affect a second ‘click’ 
reaction. This gave the dimer 63 which features two VHH nanobodies. Dimers such as 63 
were shown to have different avidity and kinetic profiles to monomers such as 61. The 
modularity of the protocol (Scheme 21) provides access to an array of conjugates. For 
example: 62 can be replaced with sortase products featuring other click handles or a PEG 
chain for solubility. Variability of these constructs was shown to have a significant effect on in 
vivo properties such as avidity, uptake and clearance profiles when targeting a range of 
targets [80]. 
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The use of enzymes for the radiolabelling of biomolecules related to PET is a new and 
relatively unexplored field. Recently lipoic acid ligase was shown to be a suitable reagent for 
the site-specific radiofluorination of biomolecules [17]. The octanoate 65 was prepared 
synthetically (3h, dcRCY 26 %) and was enzymatically coupled to Fab fragment 64 to give 
the radiolabelled amide conjugate 66 (Scheme 22). Notably, site specificity was achieved by 
introducing a LAP peptide tag into the Fab by standard cloning techniques. Enzyme 
incubation time was relatively short (10-15 min) and conjugation yields were high (~95%) 
with low loading of the Fab protein precursor (10 nmol). The lipoic acid ligase (and enzyme-
mediated transformations in general) has the benefit of utilising mild conditions which are 
unlikely to denature the protein biomolecules.  
3. Conclusion 
This review has summarised the efforts and ongoing status of radiolabelling antibodies with 
the fluorine-18 isotope, for positron emission tomography applications. The radiolabelling of 
antibodies and their fragments with fluorine-18 continues to receive ever-growing attention 
[81–83]. The account highlights the current activity and challenges in the field. It has tried to 
identify the different approaches taken using fluorine-18 prosthetic groups, combining these 
with low molecular weight antibody fragments and affibodies to match clearance rates with 
the half-life of the fluorine-18 isotope. This has required ingenuity in both isotope tagging 
strategies and antibody fragment engineering.  Last step labelling from aqueous [18F]fluoride, 
through macrocycle secured aluminium is emerging as a popular and practical method. 
Further methods using aqueous [18F]fluoride are also gaining prevalence. High-yielding 
biorthogonal click reactions can provide modular platforms for conjugates with tuneable 
avidity and kinetics, and mild enzymatic methods are likely to garner further attention in the 
future. Efforts to label full sized antibodies with fluorine-18 remains extremely challenging. 
This generally requires pre-targeting strategies, where the antibody is administered several 
days in advance of a low molecular weight [18F]-labelled tracer which finds its way to, and 
binds or reacts with the pre-localised antibody in vivo. Significant challenges remain which 
will benefit from additional innovative solutions.   
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Fig. 1. Conventional and Heavy-Chain IgG and their fragments, adapted from Joosten et al. [20]. 
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Fig.2. Compounds initially used for fluorine-18 radiolabelling of antibodies and their fragments. 
 
 
Fig. 3. Structure of 44 and 45 [75]. 
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Fig. 4. Structure of 48 [16]. 
 
 
 
Scheme 1. Radiosynthesis of 1 [13,27,28]. 
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Scheme 2. Radiosynthesis of 3 [30–34]. 
 
Scheme 3. Radiosynthesis of 9 [35,36]. 
 
Scheme 4. Radiosynthesis of 5 [12]. 
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Scheme 5. Modified radiosynthesis of 1 [39]. 
 
Scheme 6. Radiosynthesis of 21 [53]. 
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Scheme 7. Synthesis of 4 from 1 [56]. 
 
Scheme 8. Radiosynthesis of 26 [65]. 
 
Scheme 9. Radiosynthesis of 28 [66]. 
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Scheme 10. Radiosynthesis of 30 [67]. 
 
Scheme 11. Radiosynthesis of 32 [70]. 
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Scheme 12. Radiosynthesis of 34 [18]. 
 
 
Scheme 13. Radiosynthesis of 36 [71]. 
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Scheme 14. Radiosynthesis of 38 [15,72]. 
 
Scheme 15. Conjugation and radiolabelling of 39 [57]. 
 
Scheme 16. Radiosynthesis of 43 [73]. 
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Scheme 17. Radiosynthesis of 47 [76]. 
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Scheme 18. Radiosynthesis of 50 [77]. 
 
 
Scheme 189. Radiolabelling of 51 to give 52 [14]. 
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Scheme 20. Elaboration of 2 to 58 via enzymatic and click processes [79]. 
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Scheme 21. Use of modular click reactions to radiolabel nanobody monomer 61 and dimer 63 [80]. 
 
 
Scheme 22. Enzymatic radiolabelling of Fab fragment 64 by lipoic acid ligase-mediated amidation [17]. 
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